This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Classification

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

In 1982 the French-American-British (FAB) group developed a classification system for myelodysplastic syndromes (MDS) according to morphological criteria:

SUB-TYPE

DISTINGUISHING FEATURES IN MARROW

Refractory anaemia

< 5% blasts

Refractory anaemia + ringed sideroblasts

< 5% blasts; ringed sideroblasts > 15%

Refractory anaemia + excess blasts

5-20% blasts

Refractory anaemia + blasts in transformation

20-30% blasts

Chronic myelomonocytic leukaemia

blood monocytes > 1 x 10^9/l

 

The World Health Organisation (WHO) have produced a revised classification for MDS (1)

  • in this classification system refractory anemia (RA) and sideroblastic anemia (RARS) have been more strictly defined, including only cases with a predominance of cell atypias in the erythroid lineage
  • chronic myelomonocytic leukemia is reclassified under a separate category
  • a new category refractory cytopenias with multilineage dysplasias (RCMD) has been defined as MDS presenting less than bone marrow (BM) blasts, but showing cell atypias in more than 10% in two or three hemopoietic cell lines
  • the new classification also includes as a separate entity the 5q-syndrome
  • a category "unclassified" has been created in order to include cases with peripheral cytopenias, discrete atypias in granulocytes and/or megakaryocytes and BM blasts lower than 5%
  • in addition to the pathologic classification, various prognostic predictors were formatted into scoring systems. BM blast percentage, cytopenias, and cytogenetics are the backbone for those prognostic models. The International Prognostic Scoring System is a product of pooled data from previous scoring systems and a useful tool to predict survival and acute myelogenous leukemia evolution

Reference:

  1. J.W. Vardiman, N.L. Harris and R.D. Brunning, The World Health Organization classification of the myeloid neoplasms. Blood 100 (2002), pp. 2292–2302.
  2. Komrokji R, Bennet JM. The myelodysplastic syndromes: classification and prognosis. Curr Hematol Rep. 2003 May;2(3):179-85. Review.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.